Nothing Special   »   [go: up one dir, main page]

MA30523B1 - Compose tricylique et utilisation pharmaceutique de celui-ci - Google Patents

Compose tricylique et utilisation pharmaceutique de celui-ci

Info

Publication number
MA30523B1
MA30523B1 MA31489A MA31489A MA30523B1 MA 30523 B1 MA30523 B1 MA 30523B1 MA 31489 A MA31489 A MA 31489A MA 31489 A MA31489 A MA 31489A MA 30523 B1 MA30523 B1 MA 30523B1
Authority
MA
Morocco
Prior art keywords
tricyl
compound
pharmaceutical use
melatonin
prophylaxis
Prior art date
Application number
MA31489A
Other languages
English (en)
Inventor
Osamu Uchikawa
Tatsuki Koike
Yasutaka Hoashi
Takafumi Takai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA30523B1 publication Critical patent/MA30523B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé représenté par la formule, qui est utile en tant qu'agent pour la prophylaxie ou le traitement de maladies liées à l'action de la mélatonine, ou un sel de celui-ci ou analogue.
MA31489A 2006-06-19 2008-12-19 Compose tricylique et utilisation pharmaceutique de celui-ci MA30523B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19

Publications (1)

Publication Number Publication Date
MA30523B1 true MA30523B1 (fr) 2009-06-01

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31489A MA30523B1 (fr) 2006-06-19 2008-12-19 Compose tricylique et utilisation pharmaceutique de celui-ci

Country Status (36)

Country Link
US (5) US8030337B2 (fr)
EP (1) EP2029561B1 (fr)
JP (1) JP5222737B2 (fr)
KR (1) KR101442274B1 (fr)
CN (1) CN101506181B (fr)
AR (1) AR061478A1 (fr)
AU (1) AU2007261953B2 (fr)
BR (1) BRPI0713743C1 (fr)
CA (1) CA2655753C (fr)
CL (1) CL2007001779A1 (fr)
CO (1) CO6150175A2 (fr)
CR (1) CR10524A (fr)
CY (1) CY1115729T1 (fr)
DK (1) DK2029561T3 (fr)
ES (1) ES2523410T3 (fr)
GE (1) GEP20125392B (fr)
HK (1) HK1130049A1 (fr)
HR (1) HRP20141046T1 (fr)
IL (1) IL195639A0 (fr)
JO (1) JO2999B1 (fr)
MA (1) MA30523B1 (fr)
ME (2) ME01998B (fr)
MX (1) MX2008015842A (fr)
MY (1) MY158069A (fr)
NO (1) NO341739B1 (fr)
NZ (1) NZ574037A (fr)
PE (1) PE20080941A1 (fr)
PL (1) PL2029561T3 (fr)
PT (1) PT2029561E (fr)
RS (1) RS53616B1 (fr)
RU (1) RU2456278C2 (fr)
SI (1) SI2029561T1 (fr)
TW (1) TWI402261B (fr)
UA (1) UA99104C2 (fr)
WO (1) WO2007148808A1 (fr)
ZA (1) ZA200900151B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
CA2674045A1 (fr) * 2006-12-28 2008-07-17 Takeda Pharmaceutical Company Limited Compose tricyclique et son utilisation pharmaceutique
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
AU2017205722B2 (en) * 2016-01-08 2022-02-17 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
EP3400940B1 (fr) 2016-01-08 2024-08-07 Takeda Pharmaceutical Company Limited Acomposés ayant une affinité pour le récepteur de la mélatonine en tant qu'agent prophylactique ou thérapeutique du délire
MX2019004610A (es) 2016-10-19 2019-09-18 Monsanto Technology Llc Composiciones y métodos para alterar la floración y arquitectura de planta para mejorar el potencial de rendimiento.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (fr) * 1986-01-16 1991-11-19 Terumi Hachiya Derived'indenothiazole, et sa preparation
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
CA2176854A1 (fr) 1995-06-07 1996-12-08 Daniel J. Keavy Derives de n-acyl-2-arylcyclopropylmethylamine, agents melatonergiques
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
FR2742153B1 (fr) * 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PT885210E (pt) * 1996-03-08 2002-09-30 Takeda Chemical Industries Ltd Compostos triciclicos que possuem afinidade de ligacao para receptores de melatonina sua producao e utilizacao
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
EP2305219A1 (fr) * 2000-11-17 2011-04-06 Takeda Pharmaceutical Company Limited Préparations pharmaceutiques revêtues d'un enrobage contenant de la copolyvidone
JP3633895B2 (ja) 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica

Also Published As

Publication number Publication date
CL2007001779A1 (es) 2008-01-04
US20110196003A1 (en) 2011-08-11
RU2456278C2 (ru) 2012-07-20
EP2029561A1 (fr) 2009-03-04
SI2029561T1 (sl) 2014-11-28
NO341739B1 (no) 2018-01-15
TW200815376A (en) 2008-04-01
AU2007261953B2 (en) 2012-11-08
CN101506181A (zh) 2009-08-12
WO2007148808A1 (fr) 2007-12-27
ZA200900151B (en) 2010-03-31
CA2655753A1 (fr) 2007-12-27
GEP20125392B (en) 2012-02-10
HK1130049A1 (en) 2009-12-18
EP2029561B1 (fr) 2014-08-13
TWI402261B (zh) 2013-07-21
US20110190361A1 (en) 2011-08-04
ES2523410T3 (es) 2014-11-25
BRPI0713743A2 (pt) 2012-11-06
AU2007261953A1 (en) 2007-12-27
US8895591B2 (en) 2014-11-25
DK2029561T3 (da) 2014-11-10
CY1115729T1 (el) 2017-01-25
CR10524A (es) 2009-01-27
JP5222737B2 (ja) 2013-06-26
MY158069A (en) 2016-08-30
IL195639A0 (en) 2009-09-01
JP2009541202A (ja) 2009-11-26
AR061478A1 (es) 2008-08-27
RU2009101299A (ru) 2010-07-27
MX2008015842A (es) 2009-01-09
PL2029561T3 (pl) 2015-03-31
CO6150175A2 (es) 2010-04-20
BRPI0713743C1 (pt) 2021-05-25
US20130079374A1 (en) 2013-03-28
KR20090023701A (ko) 2009-03-05
US8236837B2 (en) 2012-08-07
US20090182023A1 (en) 2009-07-16
US8552037B2 (en) 2013-10-08
ME00582A (en) 2011-12-20
RS53616B1 (en) 2015-04-30
BRPI0713743B1 (pt) 2020-03-17
HRP20141046T1 (hr) 2014-12-19
PE20080941A1 (es) 2008-09-04
NZ574037A (en) 2011-10-28
CN101506181B (zh) 2011-12-07
US8030337B2 (en) 2011-10-04
US8349879B2 (en) 2013-01-08
CA2655753C (fr) 2015-08-04
PT2029561E (pt) 2014-11-12
US20140011849A1 (en) 2014-01-09
UA99104C2 (uk) 2012-07-25
JO2999B1 (ar) 2016-09-05
BRPI0713743B8 (pt) 2020-05-19
ME01998B (me) 2015-05-20
KR101442274B1 (ko) 2014-09-22
NO20090234L (no) 2009-02-12

Similar Documents

Publication Publication Date Title
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
MA47970B1 (fr) Composé inhibiteur de jak à base d'imidazo-pipéridine fusionnée
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
DE602004013563D1 (de) Rantagonisten
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
MA38454A1 (fr) Inhibiteurs de protéines kinases
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA35576B1 (fr) Nouveaux composés
MA32171B1 (fr) Compose heterocyclique
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA32283B1 (fr) Composes cycliques condenses et utilisation de ceux-ci
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения